Previous therapies
| . | 2 mg (N = 35) . | 4 mg (N = 35) . |
|---|---|---|
| No. of prior chemotherapies | ||
| 2 | 0 (0%) | 2 (5.7%) |
| 3 | 3 (8.6%) | 6 (17.1%) |
| 4 | 4 (11.4%) | 2 (5.7%) |
| 5 | 10 (28.6%) | 4 (11.4%) |
| 6 | 4 (11.4%) | 7 (20%) |
| 7 | 10 (28.6%) | 6 (17.1%) |
| 8 | 3 (8.6%) | 4 (11.4%) |
| 9 | 1 (2.9%) | 3 (8.6%) |
| 11 | 0 (0%) | 1 (2.9%) |
| Type of prior regimens | ||
| Lenalidomide | 35 (100%) | 35 (100%) |
| Bortezomib | 35 (100%) | 35 (100%) |
| Thalidomide | 22 (63%) | 20 (57%) |
| Transplantation | 27 (77%) | 28 (80%) |
| Autologous | 25 | 28 |
| Allogeneic | 2 | 0 |
| . | 2 mg (N = 35) . | 4 mg (N = 35) . |
|---|---|---|
| No. of prior chemotherapies | ||
| 2 | 0 (0%) | 2 (5.7%) |
| 3 | 3 (8.6%) | 6 (17.1%) |
| 4 | 4 (11.4%) | 2 (5.7%) |
| 5 | 10 (28.6%) | 4 (11.4%) |
| 6 | 4 (11.4%) | 7 (20%) |
| 7 | 10 (28.6%) | 6 (17.1%) |
| 8 | 3 (8.6%) | 4 (11.4%) |
| 9 | 1 (2.9%) | 3 (8.6%) |
| 11 | 0 (0%) | 1 (2.9%) |
| Type of prior regimens | ||
| Lenalidomide | 35 (100%) | 35 (100%) |
| Bortezomib | 35 (100%) | 35 (100%) |
| Thalidomide | 22 (63%) | 20 (57%) |
| Transplantation | 27 (77%) | 28 (80%) |
| Autologous | 25 | 28 |
| Allogeneic | 2 | 0 |